Unravelling molecular mechanisms in atherosclerosis using cellular models and omics technologies

Dimitris Kardassis; Cécile Vindis; Camelia Sorina Stancu; Laura Toma; Anca Violeta Gafencu; Adriana Georgescu; Nicoleta Alexandru-Moise; Filippo Molica; Brenda R. Kwak; Alexandrina Burlacu; Ignacio Fernando Hall; Elena Butoi; Paolo Magni; Junxi Wu; Susana Novella; Luke F. Gamon; Michael J. Davies; Andrea Caporali; Fernando de la Cuesta; Tijana Mitić

doi:10.1016/j.vph.2024.107452

Unravelling molecular mechanisms in atherosclerosis using cellular models and omics technologies

Dimitris Kardassis^*, Cécile Vindis, Camelia Sorina Stancu, Laura Toma, Anca Violeta Gafencu, Adriana Georgescu, Nicoleta Alexandru-Moise, Filippo Molica, Brenda R. Kwak, Alexandrina Burlacu, Ignacio Fernando Hall, Elena Butoi, Paolo Magni, Junxi Wu, Susana Novella, Luke F. Gamon, Michael J. Davies, Andrea Caporali, Fernando de la Cuesta, Tijana Mitić

^*Corresponding author af dette arbejde

Inflammation, Metabolism and Oxidation

Publikation: Bidrag til tidsskrift › Review › Forskning › peer review

1 Citationer (Scopus)

Abstract

Despite the discovery and prevalent clinical use of potent lipid-lowering therapies, including statins and PCSK9 inhibitors, cardiovascular diseases (CVD) caused by atherosclerosis remain a large unmet clinical need, accounting for frequent deaths worldwide. The pathogenesis of atherosclerosis is a complex process underlying the presence of modifiable and non-modifiable risk factors affecting several cell types including endothelial cells (ECs), monocytes/macrophages, smooth muscle cells (SMCs) and T cells. Heterogeneous composition of the plaque and its morphology could lead to rupture or erosion causing thrombosis, even a sudden death. To decipher this complexity, various cell model systems have been developed. With recent advances in systems biology approaches and single or multi-omics methods researchers can elucidate specific cell types, molecules and signalling pathways contributing to certain stages of disease progression. Compared with animals, in vitro models are economical, easily adjusted for high-throughput work, offering mechanistic insights. Hereby, we review the latest work performed employing the cellular models of atherosclerosis to generate a variety of omics data. We summarize their outputs and the impact they had in the field. Challenges in the translatability of the omics data obtained from the cell models will be discussed along with future perspectives.

Originalsprog	Engelsk
Artikelnummer	107452
Tidsskrift	Vascular Pharmacology
Vol/bind	158
Antal sider	19
ISSN	1537-1891
DOI	https://doi.org/10.1016/j.vph.2024.107452
Status	Udgivet - 2025

Bibliografisk note

Funding Information:
The present review paper discusses the advantages and disadvantages of in vitro models currently used for the study of atherosclerosis. Review is supported by the COST Action CA21153 \u201CNetwork for implementing multiomic approaches in atherosclerotic cardiovascular disease prevention and research (AtheroNET)\u201D and is the joint effort of its members. AtheroNET is aimed at providing a comprehensive framework for researchers interested in cellular and molecular research in the field of atherosclerosis as well as for clinical researchers in this area, empowering translational links between them. The network is focusing on the use of multiple omics technologies and data integration through machine learning/artificial intelligence ML/AI approached to bridge the novel paradigms in prevention, diagnosis, and treatment of atherosclerotic cardiovascular disease (ASCVD). The AtheroNET COST Action (https://atheronet.eu/) promotes specific initiatives such as the creation of inventories for in vitro and in vivo experimental models of atherosclerosis, in order to facilitate knowledge transfer; generation of technical notes, relating to the use of the models reported in the above-mentioned inventories; and review articles addressing the specific topics arising from this Action (Fig. 2).This article is based upon work from COST Action AtheroNET, CA21153, supported by COST (European Cooperation in Science and Technology). Dimitris Kardassis is supported by the Hellenic Foundation for Research and Innovation (HFRI) Research Program \u201CFunding Projects in Leading-Edge Sectors \u2013 RRFQ: Basic Research Financing (Horizontal support for all Sciences) grant No 15529 and MSCA Staff Exchanges program CardioSCOPE Grant No 101086397. Camelia Sorina Stancu is supported by the Romanian Academy, and Ministry of Research, Innovation, and Digitization, CNCS-UEFISCDI grant number: PN-III-P4-PCE-2021-0831., Laura Toma is supported by the Romanian Academy, and Ministry of Research, Innovation, and Digitization, CNCS-UEFISCDI, grant number PN-III-P2-2.1-PED-2021-1929., Anca Gafencu is supported by a grant of the Ministry of Research, Innovation and Digitization, CNCS - UEFISCDI, project number PN-III-P4-PCE-2021-1755, within PNCDI III. Adriana Georgescu and Nicoleta Alexandru-Moise are supported by the Romania's National Recovery and Resilience Plan, \u201CEuropean Union - NextGenerationEU\", PNRR-III-C9-2022-I8, CF 93/15.11.2022, Financing Contract no.760063/23.05.2023, and by the Romanian Academy. Brenda R. Kwak is supported by the Swiss National Science Foundation, grant numbers 310030_212291/1 and 310030_182573). Ignacio Fernando Hall is supported by a British Heart Foundation (BHF) individual fellowship award (FS/IPBSRF/22/27050). The work of Paolo Magni is supported in part by the European Union (CardioSCOPE 10108639 - HORIZON-MSCA-2021-SE-01-01 MSCA Staff Exchanges 2021, AtheroNET COST Action CA21153), the Italian Space Agency (ASI; N. 2023-7-HH.0 CUP F13C23000050005 MicroFunExpo) and the Italian Ministry of Health (project PNRR-MCNT2-2023-12377808, PNRR: M6/C2_CALL 2023). Junxi Wu is supported by UKRI MRC New Investigator Research Grant (NIRG) (Ref: MR/V029827/1). Susana Novella is supported by the Spanish Ministry of Science and Innovation (ISCIII) (PI19/01714; PI22/1083) co-financed by the European Regional Development Fund (ERDF) and by the Generalitat Valenciana (CIAICO 2021/211), Luke F. Gamon is supported by a HALRIC grant (20230616_PP01). Michael J. Davies is supported by the Novo Nordisk Foundation (Laureate grant NNF20SA0064214). Fernando de la Cuesta is supported by Programa de Atracci\u00F3n de Talento (Modalidad 1), Comunidad Aut\u00F3noma de Madrid 2023-5AIND-28938 and Ministerio de Ciencia, e Innovaci\u00F3n y Universidades y Fondo Europeo de Desarrollo Regional (PID2021-126274OB-I00; CNS2022-135368). Andrea Caporali and Tijana Miti\u0107 acknowledge the support of the British Heart Foundation (BHF) Project Grant (PG/22/10916). Tijana Miti\u0107 is supported by the University of Edinburgh and British Heart Foundation (BHF) Research Excellence Award REA3 (RE/18/5/34216).

Funding Information:
Susana Novella is supported by the Spanish Ministry of Science and Innovation (ISCIII) ( PI19/01714 ; PI22/1083 ) co-financed by the European Regional Development Fund (ERDF) and by the Generalitat Valenciana ( CIAICO 2021/211 ).

Funding Information:
Tijana Miti\u0107 is supported by the University of Edinburgh and British Heart Foundation (BHF) Research Excellence Award REA3 ( RE/18/5/34216 ).

Funding Information:
Dimitris Kardassis is supported by the Hellenic Foundation for Research and Innovation (HFRI) Research Program \u201CFunding Projects in Leading-Edge Sectors \u2013 RRFQ: Basic Research Financing (Horizontal support for all Sciences) grant No 15529 and MSCA Staff Exchanges program CardioSCOPE Grant No 101086397 .

Funding Information:
Adriana Georgescu is supported by the Romania's National Recovery and Resilience Plan , PNRR-III-C9-2022-I8 , CF 93/15.11.2022 , Financing Contract no. 760063/23.05.2023 , and by the Romanian Academy .

Funding Information:
This article is based upon work from COST Action AtheroNET, CA21153 , supported by COST (European Cooperation in Science and Technology).

Funding Information:
Luke F. Gamon is supported by a HALRIC grant ( 20230616_PP01 ).

Funding Information:
Anca Gafencu is supported by a grant of the Ministry of Research, Innovation and Digitization, CNCS - UEFISCDI , project number PN-III-P4-PCE-2021-1755 , within PNCDI III.

Funding Information:
Laura Toma is supported by the Romanian Academy, and Ministry of Research, Innovation, and Digitization, CNCS-UEFISCDI, grant number PN-III-P2-2.1-PED-2021-1929 .

Funding Information:
Michael J. Davies is supported by the Novo Nordisk Foundation (Laureate grant NNF20SA0064214 ).

Funding Information:
Camelia Sorina Stancu is supported by the Romanian Academy, and Ministry of Research, Innovation, and Digitization, CNCS-UEFISCDI grant number: PN-III-P4-PCE-2021-0831 .

Funding Information:
Paolo Magni is supported by HORIZON-MSCA-2021-SE-01-01 , MSCA Staff Exchanges CardioSCOPE 101086397) and by the Italian Space Agency (ASI; N. 2023-7-HH.0 CUP F13C23000050005 MicroFunExpo).

Funding Information:
Brenda R. Kwak is supported by the Swiss National Science Foundation , grant numbers 310030_212291/1 and 310030_182573 ).

Funding Information:
Ignacio Fernando Hall is supported by a British Heart Foundation (BHF) individual fellowship award ( FS/IPBSRF/22/27050 ).

Publisher Copyright:
© 2024

Adgang til dokumentet

10.1016/j.vph.2024.107452

Citationsformater

Kardassis, D., Vindis, C., Stancu, C. S., Toma, L., Gafencu, A. V., Georgescu, A., Alexandru-Moise, N., Molica, F., Kwak, B. R., Burlacu, A., Hall, I. F., Butoi, E., Magni, P., Wu, J., Novella, S., Gamon, L. F., Davies, M. J., Caporali, A., de la Cuesta, F., & Mitić, T. (2025). Unravelling molecular mechanisms in atherosclerosis using cellular models and omics technologies. Vascular Pharmacology, 158, [107452]. https://doi.org/10.1016/j.vph.2024.107452

Unravelling molecular mechanisms in atherosclerosis using cellular models and omics technologies. / Kardassis, Dimitris; Vindis, Cécile; Stancu, Camelia Sorina; Toma, Laura; Gafencu, Anca Violeta; Georgescu, Adriana; Alexandru-Moise, Nicoleta; Molica, Filippo; Kwak, Brenda R.; Burlacu, Alexandrina; Hall, Ignacio Fernando; Butoi, Elena; Magni, Paolo; Wu, Junxi; Novella, Susana; Gamon, Luke F.; Davies, Michael J.; Caporali, Andrea; de la Cuesta, Fernando; Mitić, Tijana.

I: Vascular Pharmacology, Bind 158, 107452, 2025.

Publikation: Bidrag til tidsskrift › Review › Forskning › peer review

Kardassis, D, Vindis, C, Stancu, CS, Toma, L, Gafencu, AV, Georgescu, A, Alexandru-Moise, N, Molica, F, Kwak, BR, Burlacu, A, Hall, IF, Butoi, E, Magni, P, Wu, J, Novella, S, Gamon, LF , Davies, MJ, Caporali, A, de la Cuesta, F & Mitić, T 2025, 'Unravelling molecular mechanisms in atherosclerosis using cellular models and omics technologies', Vascular Pharmacology, bind 158, 107452. https://doi.org/10.1016/j.vph.2024.107452

Kardassis, Dimitris ; Vindis, Cécile ; Stancu, Camelia Sorina ; Toma, Laura ; Gafencu, Anca Violeta ; Georgescu, Adriana ; Alexandru-Moise, Nicoleta ; Molica, Filippo ; Kwak, Brenda R. ; Burlacu, Alexandrina ; Hall, Ignacio Fernando ; Butoi, Elena ; Magni, Paolo ; Wu, Junxi ; Novella, Susana ; Gamon, Luke F. ; Davies, Michael J. ; Caporali, Andrea ; de la Cuesta, Fernando ; Mitić, Tijana. / Unravelling molecular mechanisms in atherosclerosis using cellular models and omics technologies. I: Vascular Pharmacology. 2025 ; Bind 158.

@article{ac3bacd66e0e4c6d8a23902ae36ae2f6,

title = "Unravelling molecular mechanisms in atherosclerosis using cellular models and omics technologies",

abstract = "Despite the discovery and prevalent clinical use of potent lipid-lowering therapies, including statins and PCSK9 inhibitors, cardiovascular diseases (CVD) caused by atherosclerosis remain a large unmet clinical need, accounting for frequent deaths worldwide. The pathogenesis of atherosclerosis is a complex process underlying the presence of modifiable and non-modifiable risk factors affecting several cell types including endothelial cells (ECs), monocytes/macrophages, smooth muscle cells (SMCs) and T cells. Heterogeneous composition of the plaque and its morphology could lead to rupture or erosion causing thrombosis, even a sudden death. To decipher this complexity, various cell model systems have been developed. With recent advances in systems biology approaches and single or multi-omics methods researchers can elucidate specific cell types, molecules and signalling pathways contributing to certain stages of disease progression. Compared with animals, in vitro models are economical, easily adjusted for high-throughput work, offering mechanistic insights. Hereby, we review the latest work performed employing the cellular models of atherosclerosis to generate a variety of omics data. We summarize their outputs and the impact they had in the field. Challenges in the translatability of the omics data obtained from the cell models will be discussed along with future perspectives.",

keywords = "Atherosclerosis, Omics technologies, Shear stress and circumferential stretch models, Three-dimensional (3D) models, Two dimensional (2D) models",

author = "Dimitris Kardassis and C{\'e}cile Vindis and Stancu, {Camelia Sorina} and Laura Toma and Gafencu, {Anca Violeta} and Adriana Georgescu and Nicoleta Alexandru-Moise and Filippo Molica and Kwak, {Brenda R.} and Alexandrina Burlacu and Hall, {Ignacio Fernando} and Elena Butoi and Paolo Magni and Junxi Wu and Susana Novella and Gamon, {Luke F.} and Davies, {Michael J.} and Andrea Caporali and {de la Cuesta}, Fernando and Tijana Miti{\'c}",

note = "Publisher Copyright: {\textcopyright} 2024",

year = "2025",

doi = "10.1016/j.vph.2024.107452",

language = "English",

volume = "158",

journal = "Vascular Pharmacology",

issn = "1537-1891",

publisher = "Elsevier",

}

TY - JOUR

T1 - Unravelling molecular mechanisms in atherosclerosis using cellular models and omics technologies

AU - Kardassis, Dimitris

AU - Vindis, Cécile

AU - Stancu, Camelia Sorina

AU - Toma, Laura

AU - Gafencu, Anca Violeta

AU - Georgescu, Adriana

AU - Alexandru-Moise, Nicoleta

AU - Molica, Filippo

AU - Kwak, Brenda R.

AU - Burlacu, Alexandrina

AU - Hall, Ignacio Fernando

AU - Butoi, Elena

AU - Magni, Paolo

AU - Wu, Junxi

AU - Novella, Susana

AU - Gamon, Luke F.

AU - Davies, Michael J.

AU - Caporali, Andrea

AU - de la Cuesta, Fernando

AU - Mitić, Tijana

PY - 2025

Y1 - 2025

N2 - Despite the discovery and prevalent clinical use of potent lipid-lowering therapies, including statins and PCSK9 inhibitors, cardiovascular diseases (CVD) caused by atherosclerosis remain a large unmet clinical need, accounting for frequent deaths worldwide. The pathogenesis of atherosclerosis is a complex process underlying the presence of modifiable and non-modifiable risk factors affecting several cell types including endothelial cells (ECs), monocytes/macrophages, smooth muscle cells (SMCs) and T cells. Heterogeneous composition of the plaque and its morphology could lead to rupture or erosion causing thrombosis, even a sudden death. To decipher this complexity, various cell model systems have been developed. With recent advances in systems biology approaches and single or multi-omics methods researchers can elucidate specific cell types, molecules and signalling pathways contributing to certain stages of disease progression. Compared with animals, in vitro models are economical, easily adjusted for high-throughput work, offering mechanistic insights. Hereby, we review the latest work performed employing the cellular models of atherosclerosis to generate a variety of omics data. We summarize their outputs and the impact they had in the field. Challenges in the translatability of the omics data obtained from the cell models will be discussed along with future perspectives.

AB - Despite the discovery and prevalent clinical use of potent lipid-lowering therapies, including statins and PCSK9 inhibitors, cardiovascular diseases (CVD) caused by atherosclerosis remain a large unmet clinical need, accounting for frequent deaths worldwide. The pathogenesis of atherosclerosis is a complex process underlying the presence of modifiable and non-modifiable risk factors affecting several cell types including endothelial cells (ECs), monocytes/macrophages, smooth muscle cells (SMCs) and T cells. Heterogeneous composition of the plaque and its morphology could lead to rupture or erosion causing thrombosis, even a sudden death. To decipher this complexity, various cell model systems have been developed. With recent advances in systems biology approaches and single or multi-omics methods researchers can elucidate specific cell types, molecules and signalling pathways contributing to certain stages of disease progression. Compared with animals, in vitro models are economical, easily adjusted for high-throughput work, offering mechanistic insights. Hereby, we review the latest work performed employing the cellular models of atherosclerosis to generate a variety of omics data. We summarize their outputs and the impact they had in the field. Challenges in the translatability of the omics data obtained from the cell models will be discussed along with future perspectives.

KW - Atherosclerosis

KW - Omics technologies

KW - Shear stress and circumferential stretch models

KW - Three-dimensional (3D) models

KW - Two dimensional (2D) models

U2 - 10.1016/j.vph.2024.107452

DO - 10.1016/j.vph.2024.107452

M3 - Review

C2 - 39667548

AN - SCOPUS:85212400520

VL - 158

JO - Vascular Pharmacology

JF - Vascular Pharmacology

SN - 1537-1891

M1 - 107452

ER -